The American Psychiatric Assn. in March said that to erase the risk of bias, it will phase out the $1.5 million in drugmaker money it uses to fund continuing medical education. The same month, the American College of Cardiology declined to distribute nearly half a million dollars in industry-funded, logo-branded tote bags, lanyards and badges at its annual scientific session.
The moves reflect physician organizations’ growing sensitivity about potential conflicts of interest. And if an expert panel has its way, the actions will mark the start of a shift toward reducing medical societies’ reliance on financial support from pharmaceutical companies, drugmakers and industry firms.
The whole shebang.